AbbVie Inc. $ABBV Stock: Lmcg Investments LLC Decreases Stake

Lmcg Investments LLC decreased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 5.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 132,173 shares of the company’s stock after selling 7,633 shares during the period. AbbVie comprises approximately 1.8% of Lmcg Investments LLC’s portfolio, making the stock its 8th biggest holding. Lmcg Investments LLC’s holdings in AbbVie were worth $34,575,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ABBV. Corient Private Wealth LP bought a new stake in shares of AbbVie during the second quarter valued at approximately $559,736,000. Legal & General Group Plc bought a new position in AbbVie during the 2nd quarter valued at about $2,905,952,000. Jupiter Topco LLC bought a new position in shares of AbbVie in the second quarter valued at approximately $1,560,354,000. Diamant Asset Management Inc. boosted its stake in AbbVie by 21,649.0% in the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock worth $798,456,000 after purchasing an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in AbbVie during the 2nd quarter worth about $817,473,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Lutikizumab met its Phase 3 INTREPID trial objectives. AbbVie reported that the experimental treatment for moderate-to-severe hidradenitis suppurativa achieved its primary HiSCR75 endpoint and eight ranked secondary endpoints, including reduced skin pain and fewer disease flares. The drug was generally well tolerated, with no new safety concerns. AbbVie INTREPID Phase 3 results
• Positive Sentiment: Investors continue to see potential in AbbVie’s broader immunology pipeline. Phase 2a results for a possible Skyrizi successor in Crohn’s disease and a promising eczema candidate could help support growth as AbbVie prepares for future patent expirations. Great News for AbbVie Stock Investors
• Neutral Sentiment: The INTREPID results were positive but commercially ambiguous. Although lutikizumab reduced abscess burden and met prespecified endpoints, the magnitude of benefit reportedly fell short of analyst benchmarks. That raises questions about the drug’s competitive positioning and potential sales opportunity, despite the successful trial. AbbVie skin disease drug Phase 3 results
• Negative Sentiment: Analysts characterized the efficacy as underwhelming. Lutikizumab beat placebo by roughly eight percentage points on its main measure, but the result lagged some efficacy benchmarks. Shares of rival MoonLake rose on expectations that its competing hidradenitis suppurativa therapy may remain better positioned. MoonLake reaction to AbbVie trial data
• Negative Sentiment: AbbVie halted an early-stage liver-cancer combination study. The discontinued Phase 1b trial removes one development program from the oncology pipeline, although its financial impact is likely limited compared with the company’s late-stage immunology portfolio. AbbVie liver cancer trial update

Insider Activity at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

AbbVie Price Performance

Shares of NYSE ABBV opened at $284.59 on Friday. AbbVie Inc. has a one year low of $190.75 and a one year high of $291.40. The firm has a market cap of $502.80 billion, a price-to-earnings ratio of 80.39, a P/E/G ratio of 1.30 and a beta of 0.24. The stock’s fifty day moving average price is $265.60 and its two-hundred day moving average price is $241.46.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the previous year, the firm earned $2.97 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie’s dividend payout ratio is presently 195.48%.

Wall Street Analyst Weigh In

A number of research analysts have commented on ABBV shares. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and increased their price objective for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Scotiabank upped their target price on shares of AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Cantor Fitzgerald boosted their price objective on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Finally, Citigroup boosted their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.07.

Get Our Latest Report on AbbVie

About AbbVie

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Featured Stories

• Five stocks we like better than AbbVie
• Is Texas Instruments Setting Up for Its Next Big Breakout?
• Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
• Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
• Tesla’s Flying-Car Hype Hits an Earnings Reality Check

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).